The U.S.–EU Transatlantic Administrative Simplication Plan continues on the road of development.
Leaders from both sides of the Atlantic shared the stage in late March to provide DIA EuroMeeting attendees with an update on the U.S.-EU Transatlantic Administrative Simplification Plan. Speaking on behalf of their agencies were Thomas Lönngren, executive director of EMEA, and Murray Lumpkin, MD, FDA's deputy commissioner for international programs.
FDA's Dr. Murray Lumpkin described the transatlantic initiative as a "relationship that began in earnest 10 years ago."
From the sound of things, it's smooth waters for the Transatlantic plan, which is taking the relationship to the next level. This summer, as part of an employee exchange program, FDA will send one staff member to London to set up office at EMEA headquarters. The two-year, permanent position was awarded to Janice Soreth, MD, deputy director, medical products, Europe/OIP/FDA.
Soreth's EU counterpart, who will head to the American capital, has not been selected yet. Lönngren joked that a decision would be made once the giant package of rules on his chair was read, eventually predicting this autumn as the earliest EMEA would get the ball rolling.
Amidst humor, he made his feelings clear about the exchange, calling it a "milestone, where we are bringing two agencies together."
Wide Array of Shared Interests
The amiable Lumpkin expressed excitement over the upcoming employee transplants. But no sooner did he take the podium than he told the audience he wanted them to walk away aware that both agencies have "quite extensive" relationships beyond the Transatlantic plan. "[It's] a very important one," he said, "but in reality, we have relationships at a process level that go on at a daily basis and go on at the technical level as well"—and these relationships, according to his calculations, result in 1000s of document exchanges every year.
Nonetheless, Lumpkin admits nowadays it's hard to imagine not working with the EU on a business level with the Transatlantic plan, which requires both sides follow two rules in their quest for simplification. They cannot take on projects that reduce public health protection or projects that require any changes to legislation.
What they have taken on so far does please pharma, says Ali Harrison, vice president of European regulatory affairs at AstraZeneca, who provided a personal perspective from industry on the U.S.-EU simplification plan.
Industry is extremely supportive of all activities, Harrison told the audience, and interested in dialogue. "This is a great forum to share information," she said, referring to DIA, "but we'd like to see more engagement."
Personally, she would also like to see—"just suggestions"—projects in pediatric applications, risk management plans, and patient reported outcomes (PROs). "Anything that simplifies things is welcome," Harrison said, adding that "it would be great if one set of responses would be sufficient for both agencies."
In the meantime, both sides say they will continue to figure out ways to take the relationship further in their transatlantic endeavor to improve public health through simplification.—Kerri Nelen
For an in-depth listing of projects, visit
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.